Global (United States, European Union and China) IBS Treatment

IBS Treatment Comprehensive Study by Type (IBS-D, IBS-C, IBS-M), Application (Hospitals, Clinics, Research Laboratories), Drug (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Others), Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza) Players and Region - Global Market Outlook to 2030

IBS Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About IBS Treatment
Irritable bowel syndrome (IBS) is a common disorder that affects the large intestine. Signs and symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. Only a small number of people with IBS have severe signs and symptoms. Some people can control their symptoms by managing diet, lifestyle and stress. More-severe symptoms can be treated with medication and counseling. Rising prevalence of gastrointestinal diseases and disorder, geriatric population, unhealthy diet, anxiety, depression, and changing lifestyle are the key drivers of the IBS market. Moreover, strong clinical pipeline and government support is fuelling the market in this region.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The market is highly fragmented with the presence of various players in the market. Some of the key strategies followed by the players operating in the market were innovation, product development, acquisition, and expansion. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global IBS Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Novartis AG (Switzerland), Abbott Laboratories (United States), Synergy Pharmaceuticals, Inc. (United States), Allergan Plc (Ireland), Sucampo Pharmaceuticals (United States), Ironwood Pharmaceuticals, Inc. (United States), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Ardelyx, Inc. (United States) and Sebela Pharmaceuticals (Ireland) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Probi (Sweden), Alfasigma USA, Inc. (Italy), RedHill Biopharma Ltd. (Israel), AstraZeneca (United Kingdom), Ipsen (France), Takeda Pharmaceutical Company Ltd (Japan) and Synthetic Biologics, Inc. (United States).

Segmentation Overview
AMA Research has segmented the market of Global IBS Treatment market by Type (IBS-D, IBS-C and IBS-M), Application (Hospitals, Clinics and Research Laboratories) and Region.



On the basis of geography, the market of IBS Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Drug, the sub-segment i.e. Lubiprostone will boost the IBS Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Product, the sub-segment i.e. Xifaxan will boost the IBS Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Growing adoption of inorganic strategies by manufacturer

Market Growth Drivers:
Increase prevalence of irritable bowel syndrome among the population and Increase in research and development of new therapeutic products for the treatments of IBS

Challenges:
Lack of expertise

Restraints:
Side effects associated with various drugs taken in curing IBS

Opportunities:
Increasing investments and funding in the field of life science

Market Leaders and their expansionary development strategies
In February 2021, Seed Health, a microbial sciences company, acquired of Auggi, a digital health company with a suite of artificial intelligence and machine learning technologies to track and analyze digestive health. Seed Health will acquire Auggi's technology assets, including its AI algorithm for real-time Bristol stool typing, the world's largest stool image database, and a mobile monitoring application for clinical research.
In April 2022, Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, developed and commercialize innovative first-in-class medicines that meet significant unmet medical launched of IBSRELA, the first and only NHE3 inhibitor for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. IBSRELA is the first FDA-approved product for Ardelyx.


Key Target Audience
Academic research institute, Pharmaceuticals companies, Biotechnology companies, Contract research organization and Market research and consulting firms

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • IBS-D
  • IBS-C
  • IBS-M
By Application
  • Hospitals
  • Clinics
  • Research Laboratories
By Drug
  • Lubiprostone
  • Linaclotide
  • Eluxadoline
  • Rifaximin
  • Alosetron
  • Others

By Product
  • Xifaxan
  • Linzess/Constella
  • Viberzi
  • Amitiza

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase prevalence of irritable bowel syndrome among the population
      • 3.2.2. Increase in research and development of new therapeutic products for the treatments of IBS
    • 3.3. Market Challenges
      • 3.3.1. Lack of expertise
    • 3.4. Market Trends
      • 3.4.1. Growing adoption of inorganic strategies by manufacturer
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global IBS Treatment, by Type, Application, Drug, Product and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global IBS Treatment (Value)
      • 5.2.1. Global IBS Treatment by: Type (Value)
        • 5.2.1.1. IBS-D
        • 5.2.1.2. IBS-C
        • 5.2.1.3. IBS-M
      • 5.2.2. Global IBS Treatment by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Research Laboratories
      • 5.2.3. Global IBS Treatment by: Drug (Value)
        • 5.2.3.1. Lubiprostone
        • 5.2.3.2. Linaclotide
        • 5.2.3.3. Eluxadoline
        • 5.2.3.4. Rifaximin
        • 5.2.3.5. Alosetron
        • 5.2.3.6. Others
      • 5.2.4. Global IBS Treatment by: Product (Value)
        • 5.2.4.1. Xifaxan
        • 5.2.4.2. Linzess/Constella
        • 5.2.4.3. Viberzi
        • 5.2.4.4. Amitiza
      • 5.2.5. Global IBS Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. IBS Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Novartis AG (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Synergy Pharmaceuticals, Inc. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Allergan Plc (Ireland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Sucampo Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Ironwood Pharmaceuticals, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Astellas Pharma Inc. (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Valeant Pharmaceuticals (Canada)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Ardelyx, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Sebela Pharmaceuticals (Ireland)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global IBS Treatment Sale, by Type, Application, Drug, Product and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global IBS Treatment (Value)
      • 7.2.1. Global IBS Treatment by: Type (Value)
        • 7.2.1.1. IBS-D
        • 7.2.1.2. IBS-C
        • 7.2.1.3. IBS-M
      • 7.2.2. Global IBS Treatment by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Research Laboratories
      • 7.2.3. Global IBS Treatment by: Drug (Value)
        • 7.2.3.1. Lubiprostone
        • 7.2.3.2. Linaclotide
        • 7.2.3.3. Eluxadoline
        • 7.2.3.4. Rifaximin
        • 7.2.3.5. Alosetron
        • 7.2.3.6. Others
      • 7.2.4. Global IBS Treatment by: Product (Value)
        • 7.2.4.1. Xifaxan
        • 7.2.4.2. Linzess/Constella
        • 7.2.4.3. Viberzi
        • 7.2.4.4. Amitiza
      • 7.2.5. Global IBS Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. IBS Treatment: by Type(USD Million)
  • Table 2. IBS Treatment IBS-D , by Region USD Million (2018-2023)
  • Table 3. IBS Treatment IBS-C , by Region USD Million (2018-2023)
  • Table 4. IBS Treatment IBS-M , by Region USD Million (2018-2023)
  • Table 5. IBS Treatment: by Application(USD Million)
  • Table 6. IBS Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 7. IBS Treatment Clinics , by Region USD Million (2018-2023)
  • Table 8. IBS Treatment Research Laboratories , by Region USD Million (2018-2023)
  • Table 9. IBS Treatment: by Drug(USD Million)
  • Table 10. IBS Treatment Lubiprostone , by Region USD Million (2018-2023)
  • Table 11. IBS Treatment Linaclotide , by Region USD Million (2018-2023)
  • Table 12. IBS Treatment Eluxadoline , by Region USD Million (2018-2023)
  • Table 13. IBS Treatment Rifaximin , by Region USD Million (2018-2023)
  • Table 14. IBS Treatment Alosetron , by Region USD Million (2018-2023)
  • Table 15. IBS Treatment Others , by Region USD Million (2018-2023)
  • Table 16. IBS Treatment: by Product(USD Million)
  • Table 17. IBS Treatment Xifaxan , by Region USD Million (2018-2023)
  • Table 18. IBS Treatment Linzess/Constella , by Region USD Million (2018-2023)
  • Table 19. IBS Treatment Viberzi , by Region USD Million (2018-2023)
  • Table 20. IBS Treatment Amitiza , by Region USD Million (2018-2023)
  • Table 21. South America IBS Treatment, by Country USD Million (2018-2023)
  • Table 22. South America IBS Treatment, by Type USD Million (2018-2023)
  • Table 23. South America IBS Treatment, by Application USD Million (2018-2023)
  • Table 24. South America IBS Treatment, by Drug USD Million (2018-2023)
  • Table 25. South America IBS Treatment, by Product USD Million (2018-2023)
  • Table 26. Brazil IBS Treatment, by Type USD Million (2018-2023)
  • Table 27. Brazil IBS Treatment, by Application USD Million (2018-2023)
  • Table 28. Brazil IBS Treatment, by Drug USD Million (2018-2023)
  • Table 29. Brazil IBS Treatment, by Product USD Million (2018-2023)
  • Table 30. Argentina IBS Treatment, by Type USD Million (2018-2023)
  • Table 31. Argentina IBS Treatment, by Application USD Million (2018-2023)
  • Table 32. Argentina IBS Treatment, by Drug USD Million (2018-2023)
  • Table 33. Argentina IBS Treatment, by Product USD Million (2018-2023)
  • Table 34. Rest of South America IBS Treatment, by Type USD Million (2018-2023)
  • Table 35. Rest of South America IBS Treatment, by Application USD Million (2018-2023)
  • Table 36. Rest of South America IBS Treatment, by Drug USD Million (2018-2023)
  • Table 37. Rest of South America IBS Treatment, by Product USD Million (2018-2023)
  • Table 38. Asia Pacific IBS Treatment, by Country USD Million (2018-2023)
  • Table 39. Asia Pacific IBS Treatment, by Type USD Million (2018-2023)
  • Table 40. Asia Pacific IBS Treatment, by Application USD Million (2018-2023)
  • Table 41. Asia Pacific IBS Treatment, by Drug USD Million (2018-2023)
  • Table 42. Asia Pacific IBS Treatment, by Product USD Million (2018-2023)
  • Table 43. China IBS Treatment, by Type USD Million (2018-2023)
  • Table 44. China IBS Treatment, by Application USD Million (2018-2023)
  • Table 45. China IBS Treatment, by Drug USD Million (2018-2023)
  • Table 46. China IBS Treatment, by Product USD Million (2018-2023)
  • Table 47. Japan IBS Treatment, by Type USD Million (2018-2023)
  • Table 48. Japan IBS Treatment, by Application USD Million (2018-2023)
  • Table 49. Japan IBS Treatment, by Drug USD Million (2018-2023)
  • Table 50. Japan IBS Treatment, by Product USD Million (2018-2023)
  • Table 51. India IBS Treatment, by Type USD Million (2018-2023)
  • Table 52. India IBS Treatment, by Application USD Million (2018-2023)
  • Table 53. India IBS Treatment, by Drug USD Million (2018-2023)
  • Table 54. India IBS Treatment, by Product USD Million (2018-2023)
  • Table 55. South Korea IBS Treatment, by Type USD Million (2018-2023)
  • Table 56. South Korea IBS Treatment, by Application USD Million (2018-2023)
  • Table 57. South Korea IBS Treatment, by Drug USD Million (2018-2023)
  • Table 58. South Korea IBS Treatment, by Product USD Million (2018-2023)
  • Table 59. Taiwan IBS Treatment, by Type USD Million (2018-2023)
  • Table 60. Taiwan IBS Treatment, by Application USD Million (2018-2023)
  • Table 61. Taiwan IBS Treatment, by Drug USD Million (2018-2023)
  • Table 62. Taiwan IBS Treatment, by Product USD Million (2018-2023)
  • Table 63. Australia IBS Treatment, by Type USD Million (2018-2023)
  • Table 64. Australia IBS Treatment, by Application USD Million (2018-2023)
  • Table 65. Australia IBS Treatment, by Drug USD Million (2018-2023)
  • Table 66. Australia IBS Treatment, by Product USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific IBS Treatment, by Type USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific IBS Treatment, by Application USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific IBS Treatment, by Drug USD Million (2018-2023)
  • Table 70. Rest of Asia-Pacific IBS Treatment, by Product USD Million (2018-2023)
  • Table 71. Europe IBS Treatment, by Country USD Million (2018-2023)
  • Table 72. Europe IBS Treatment, by Type USD Million (2018-2023)
  • Table 73. Europe IBS Treatment, by Application USD Million (2018-2023)
  • Table 74. Europe IBS Treatment, by Drug USD Million (2018-2023)
  • Table 75. Europe IBS Treatment, by Product USD Million (2018-2023)
  • Table 76. Germany IBS Treatment, by Type USD Million (2018-2023)
  • Table 77. Germany IBS Treatment, by Application USD Million (2018-2023)
  • Table 78. Germany IBS Treatment, by Drug USD Million (2018-2023)
  • Table 79. Germany IBS Treatment, by Product USD Million (2018-2023)
  • Table 80. France IBS Treatment, by Type USD Million (2018-2023)
  • Table 81. France IBS Treatment, by Application USD Million (2018-2023)
  • Table 82. France IBS Treatment, by Drug USD Million (2018-2023)
  • Table 83. France IBS Treatment, by Product USD Million (2018-2023)
  • Table 84. Italy IBS Treatment, by Type USD Million (2018-2023)
  • Table 85. Italy IBS Treatment, by Application USD Million (2018-2023)
  • Table 86. Italy IBS Treatment, by Drug USD Million (2018-2023)
  • Table 87. Italy IBS Treatment, by Product USD Million (2018-2023)
  • Table 88. United Kingdom IBS Treatment, by Type USD Million (2018-2023)
  • Table 89. United Kingdom IBS Treatment, by Application USD Million (2018-2023)
  • Table 90. United Kingdom IBS Treatment, by Drug USD Million (2018-2023)
  • Table 91. United Kingdom IBS Treatment, by Product USD Million (2018-2023)
  • Table 92. Netherlands IBS Treatment, by Type USD Million (2018-2023)
  • Table 93. Netherlands IBS Treatment, by Application USD Million (2018-2023)
  • Table 94. Netherlands IBS Treatment, by Drug USD Million (2018-2023)
  • Table 95. Netherlands IBS Treatment, by Product USD Million (2018-2023)
  • Table 96. Rest of Europe IBS Treatment, by Type USD Million (2018-2023)
  • Table 97. Rest of Europe IBS Treatment, by Application USD Million (2018-2023)
  • Table 98. Rest of Europe IBS Treatment, by Drug USD Million (2018-2023)
  • Table 99. Rest of Europe IBS Treatment, by Product USD Million (2018-2023)
  • Table 100. MEA IBS Treatment, by Country USD Million (2018-2023)
  • Table 101. MEA IBS Treatment, by Type USD Million (2018-2023)
  • Table 102. MEA IBS Treatment, by Application USD Million (2018-2023)
  • Table 103. MEA IBS Treatment, by Drug USD Million (2018-2023)
  • Table 104. MEA IBS Treatment, by Product USD Million (2018-2023)
  • Table 105. Middle East IBS Treatment, by Type USD Million (2018-2023)
  • Table 106. Middle East IBS Treatment, by Application USD Million (2018-2023)
  • Table 107. Middle East IBS Treatment, by Drug USD Million (2018-2023)
  • Table 108. Middle East IBS Treatment, by Product USD Million (2018-2023)
  • Table 109. Africa IBS Treatment, by Type USD Million (2018-2023)
  • Table 110. Africa IBS Treatment, by Application USD Million (2018-2023)
  • Table 111. Africa IBS Treatment, by Drug USD Million (2018-2023)
  • Table 112. Africa IBS Treatment, by Product USD Million (2018-2023)
  • Table 113. North America IBS Treatment, by Country USD Million (2018-2023)
  • Table 114. North America IBS Treatment, by Type USD Million (2018-2023)
  • Table 115. North America IBS Treatment, by Application USD Million (2018-2023)
  • Table 116. North America IBS Treatment, by Drug USD Million (2018-2023)
  • Table 117. North America IBS Treatment, by Product USD Million (2018-2023)
  • Table 118. United States IBS Treatment, by Type USD Million (2018-2023)
  • Table 119. United States IBS Treatment, by Application USD Million (2018-2023)
  • Table 120. United States IBS Treatment, by Drug USD Million (2018-2023)
  • Table 121. United States IBS Treatment, by Product USD Million (2018-2023)
  • Table 122. Canada IBS Treatment, by Type USD Million (2018-2023)
  • Table 123. Canada IBS Treatment, by Application USD Million (2018-2023)
  • Table 124. Canada IBS Treatment, by Drug USD Million (2018-2023)
  • Table 125. Canada IBS Treatment, by Product USD Million (2018-2023)
  • Table 126. Mexico IBS Treatment, by Type USD Million (2018-2023)
  • Table 127. Mexico IBS Treatment, by Application USD Million (2018-2023)
  • Table 128. Mexico IBS Treatment, by Drug USD Million (2018-2023)
  • Table 129. Mexico IBS Treatment, by Product USD Million (2018-2023)
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. IBS Treatment: by Type(USD Million)
  • Table 141. IBS Treatment IBS-D , by Region USD Million (2025-2030)
  • Table 142. IBS Treatment IBS-C , by Region USD Million (2025-2030)
  • Table 143. IBS Treatment IBS-M , by Region USD Million (2025-2030)
  • Table 144. IBS Treatment: by Application(USD Million)
  • Table 145. IBS Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 146. IBS Treatment Clinics , by Region USD Million (2025-2030)
  • Table 147. IBS Treatment Research Laboratories , by Region USD Million (2025-2030)
  • Table 148. IBS Treatment: by Drug(USD Million)
  • Table 149. IBS Treatment Lubiprostone , by Region USD Million (2025-2030)
  • Table 150. IBS Treatment Linaclotide , by Region USD Million (2025-2030)
  • Table 151. IBS Treatment Eluxadoline , by Region USD Million (2025-2030)
  • Table 152. IBS Treatment Rifaximin , by Region USD Million (2025-2030)
  • Table 153. IBS Treatment Alosetron , by Region USD Million (2025-2030)
  • Table 154. IBS Treatment Others , by Region USD Million (2025-2030)
  • Table 155. IBS Treatment: by Product(USD Million)
  • Table 156. IBS Treatment Xifaxan , by Region USD Million (2025-2030)
  • Table 157. IBS Treatment Linzess/Constella , by Region USD Million (2025-2030)
  • Table 158. IBS Treatment Viberzi , by Region USD Million (2025-2030)
  • Table 159. IBS Treatment Amitiza , by Region USD Million (2025-2030)
  • Table 160. South America IBS Treatment, by Country USD Million (2025-2030)
  • Table 161. South America IBS Treatment, by Type USD Million (2025-2030)
  • Table 162. South America IBS Treatment, by Application USD Million (2025-2030)
  • Table 163. South America IBS Treatment, by Drug USD Million (2025-2030)
  • Table 164. South America IBS Treatment, by Product USD Million (2025-2030)
  • Table 165. Brazil IBS Treatment, by Type USD Million (2025-2030)
  • Table 166. Brazil IBS Treatment, by Application USD Million (2025-2030)
  • Table 167. Brazil IBS Treatment, by Drug USD Million (2025-2030)
  • Table 168. Brazil IBS Treatment, by Product USD Million (2025-2030)
  • Table 169. Argentina IBS Treatment, by Type USD Million (2025-2030)
  • Table 170. Argentina IBS Treatment, by Application USD Million (2025-2030)
  • Table 171. Argentina IBS Treatment, by Drug USD Million (2025-2030)
  • Table 172. Argentina IBS Treatment, by Product USD Million (2025-2030)
  • Table 173. Rest of South America IBS Treatment, by Type USD Million (2025-2030)
  • Table 174. Rest of South America IBS Treatment, by Application USD Million (2025-2030)
  • Table 175. Rest of South America IBS Treatment, by Drug USD Million (2025-2030)
  • Table 176. Rest of South America IBS Treatment, by Product USD Million (2025-2030)
  • Table 177. Asia Pacific IBS Treatment, by Country USD Million (2025-2030)
  • Table 178. Asia Pacific IBS Treatment, by Type USD Million (2025-2030)
  • Table 179. Asia Pacific IBS Treatment, by Application USD Million (2025-2030)
  • Table 180. Asia Pacific IBS Treatment, by Drug USD Million (2025-2030)
  • Table 181. Asia Pacific IBS Treatment, by Product USD Million (2025-2030)
  • Table 182. China IBS Treatment, by Type USD Million (2025-2030)
  • Table 183. China IBS Treatment, by Application USD Million (2025-2030)
  • Table 184. China IBS Treatment, by Drug USD Million (2025-2030)
  • Table 185. China IBS Treatment, by Product USD Million (2025-2030)
  • Table 186. Japan IBS Treatment, by Type USD Million (2025-2030)
  • Table 187. Japan IBS Treatment, by Application USD Million (2025-2030)
  • Table 188. Japan IBS Treatment, by Drug USD Million (2025-2030)
  • Table 189. Japan IBS Treatment, by Product USD Million (2025-2030)
  • Table 190. India IBS Treatment, by Type USD Million (2025-2030)
  • Table 191. India IBS Treatment, by Application USD Million (2025-2030)
  • Table 192. India IBS Treatment, by Drug USD Million (2025-2030)
  • Table 193. India IBS Treatment, by Product USD Million (2025-2030)
  • Table 194. South Korea IBS Treatment, by Type USD Million (2025-2030)
  • Table 195. South Korea IBS Treatment, by Application USD Million (2025-2030)
  • Table 196. South Korea IBS Treatment, by Drug USD Million (2025-2030)
  • Table 197. South Korea IBS Treatment, by Product USD Million (2025-2030)
  • Table 198. Taiwan IBS Treatment, by Type USD Million (2025-2030)
  • Table 199. Taiwan IBS Treatment, by Application USD Million (2025-2030)
  • Table 200. Taiwan IBS Treatment, by Drug USD Million (2025-2030)
  • Table 201. Taiwan IBS Treatment, by Product USD Million (2025-2030)
  • Table 202. Australia IBS Treatment, by Type USD Million (2025-2030)
  • Table 203. Australia IBS Treatment, by Application USD Million (2025-2030)
  • Table 204. Australia IBS Treatment, by Drug USD Million (2025-2030)
  • Table 205. Australia IBS Treatment, by Product USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific IBS Treatment, by Type USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific IBS Treatment, by Application USD Million (2025-2030)
  • Table 208. Rest of Asia-Pacific IBS Treatment, by Drug USD Million (2025-2030)
  • Table 209. Rest of Asia-Pacific IBS Treatment, by Product USD Million (2025-2030)
  • Table 210. Europe IBS Treatment, by Country USD Million (2025-2030)
  • Table 211. Europe IBS Treatment, by Type USD Million (2025-2030)
  • Table 212. Europe IBS Treatment, by Application USD Million (2025-2030)
  • Table 213. Europe IBS Treatment, by Drug USD Million (2025-2030)
  • Table 214. Europe IBS Treatment, by Product USD Million (2025-2030)
  • Table 215. Germany IBS Treatment, by Type USD Million (2025-2030)
  • Table 216. Germany IBS Treatment, by Application USD Million (2025-2030)
  • Table 217. Germany IBS Treatment, by Drug USD Million (2025-2030)
  • Table 218. Germany IBS Treatment, by Product USD Million (2025-2030)
  • Table 219. France IBS Treatment, by Type USD Million (2025-2030)
  • Table 220. France IBS Treatment, by Application USD Million (2025-2030)
  • Table 221. France IBS Treatment, by Drug USD Million (2025-2030)
  • Table 222. France IBS Treatment, by Product USD Million (2025-2030)
  • Table 223. Italy IBS Treatment, by Type USD Million (2025-2030)
  • Table 224. Italy IBS Treatment, by Application USD Million (2025-2030)
  • Table 225. Italy IBS Treatment, by Drug USD Million (2025-2030)
  • Table 226. Italy IBS Treatment, by Product USD Million (2025-2030)
  • Table 227. United Kingdom IBS Treatment, by Type USD Million (2025-2030)
  • Table 228. United Kingdom IBS Treatment, by Application USD Million (2025-2030)
  • Table 229. United Kingdom IBS Treatment, by Drug USD Million (2025-2030)
  • Table 230. United Kingdom IBS Treatment, by Product USD Million (2025-2030)
  • Table 231. Netherlands IBS Treatment, by Type USD Million (2025-2030)
  • Table 232. Netherlands IBS Treatment, by Application USD Million (2025-2030)
  • Table 233. Netherlands IBS Treatment, by Drug USD Million (2025-2030)
  • Table 234. Netherlands IBS Treatment, by Product USD Million (2025-2030)
  • Table 235. Rest of Europe IBS Treatment, by Type USD Million (2025-2030)
  • Table 236. Rest of Europe IBS Treatment, by Application USD Million (2025-2030)
  • Table 237. Rest of Europe IBS Treatment, by Drug USD Million (2025-2030)
  • Table 238. Rest of Europe IBS Treatment, by Product USD Million (2025-2030)
  • Table 239. MEA IBS Treatment, by Country USD Million (2025-2030)
  • Table 240. MEA IBS Treatment, by Type USD Million (2025-2030)
  • Table 241. MEA IBS Treatment, by Application USD Million (2025-2030)
  • Table 242. MEA IBS Treatment, by Drug USD Million (2025-2030)
  • Table 243. MEA IBS Treatment, by Product USD Million (2025-2030)
  • Table 244. Middle East IBS Treatment, by Type USD Million (2025-2030)
  • Table 245. Middle East IBS Treatment, by Application USD Million (2025-2030)
  • Table 246. Middle East IBS Treatment, by Drug USD Million (2025-2030)
  • Table 247. Middle East IBS Treatment, by Product USD Million (2025-2030)
  • Table 248. Africa IBS Treatment, by Type USD Million (2025-2030)
  • Table 249. Africa IBS Treatment, by Application USD Million (2025-2030)
  • Table 250. Africa IBS Treatment, by Drug USD Million (2025-2030)
  • Table 251. Africa IBS Treatment, by Product USD Million (2025-2030)
  • Table 252. North America IBS Treatment, by Country USD Million (2025-2030)
  • Table 253. North America IBS Treatment, by Type USD Million (2025-2030)
  • Table 254. North America IBS Treatment, by Application USD Million (2025-2030)
  • Table 255. North America IBS Treatment, by Drug USD Million (2025-2030)
  • Table 256. North America IBS Treatment, by Product USD Million (2025-2030)
  • Table 257. United States IBS Treatment, by Type USD Million (2025-2030)
  • Table 258. United States IBS Treatment, by Application USD Million (2025-2030)
  • Table 259. United States IBS Treatment, by Drug USD Million (2025-2030)
  • Table 260. United States IBS Treatment, by Product USD Million (2025-2030)
  • Table 261. Canada IBS Treatment, by Type USD Million (2025-2030)
  • Table 262. Canada IBS Treatment, by Application USD Million (2025-2030)
  • Table 263. Canada IBS Treatment, by Drug USD Million (2025-2030)
  • Table 264. Canada IBS Treatment, by Product USD Million (2025-2030)
  • Table 265. Mexico IBS Treatment, by Type USD Million (2025-2030)
  • Table 266. Mexico IBS Treatment, by Application USD Million (2025-2030)
  • Table 267. Mexico IBS Treatment, by Drug USD Million (2025-2030)
  • Table 268. Mexico IBS Treatment, by Product USD Million (2025-2030)
  • Table 269. Research Programs/Design for This Report
  • Table 270. Key Data Information from Secondary Sources
  • Table 271. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global IBS Treatment: by Type USD Million (2018-2023)
  • Figure 5. Global IBS Treatment: by Application USD Million (2018-2023)
  • Figure 6. Global IBS Treatment: by Drug USD Million (2018-2023)
  • Figure 7. Global IBS Treatment: by Product USD Million (2018-2023)
  • Figure 8. South America IBS Treatment Share (%), by Country
  • Figure 9. Asia Pacific IBS Treatment Share (%), by Country
  • Figure 10. Europe IBS Treatment Share (%), by Country
  • Figure 11. MEA IBS Treatment Share (%), by Country
  • Figure 12. North America IBS Treatment Share (%), by Country
  • Figure 13. Global IBS Treatment share by Players 2023 (%)
  • Figure 14. Global IBS Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global IBS Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Novartis AG (Switzerland) Revenue: by Geography 2023
  • Figure 19. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 20. Abbott Laboratories (United States) Revenue: by Geography 2023
  • Figure 21. Synergy Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 22. Synergy Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 23. Allergan Plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 24. Allergan Plc (Ireland) Revenue: by Geography 2023
  • Figure 25. Sucampo Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 26. Sucampo Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 27. Ironwood Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Ironwood Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. Astellas Pharma Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 30. Astellas Pharma Inc. (Japan) Revenue: by Geography 2023
  • Figure 31. Valeant Pharmaceuticals (Canada) Revenue, Net Income and Gross profit
  • Figure 32. Valeant Pharmaceuticals (Canada) Revenue: by Geography 2023
  • Figure 33. Ardelyx, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Ardelyx, Inc. (United States) Revenue: by Geography 2023
  • Figure 35. Sebela Pharmaceuticals (Ireland) Revenue, Net Income and Gross profit
  • Figure 36. Sebela Pharmaceuticals (Ireland) Revenue: by Geography 2023
  • Figure 37. Global IBS Treatment: by Type USD Million (2025-2030)
  • Figure 38. Global IBS Treatment: by Application USD Million (2025-2030)
  • Figure 39. Global IBS Treatment: by Drug USD Million (2025-2030)
  • Figure 40. Global IBS Treatment: by Product USD Million (2025-2030)
  • Figure 41. South America IBS Treatment Share (%), by Country
  • Figure 42. Asia Pacific IBS Treatment Share (%), by Country
  • Figure 43. Europe IBS Treatment Share (%), by Country
  • Figure 44. MEA IBS Treatment Share (%), by Country
  • Figure 45. North America IBS Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Novartis AG (Switzerland)
  • Abbott Laboratories (United States)
  • Synergy Pharmaceuticals, Inc. (United States)
  • Allergan Plc (Ireland)
  • Sucampo Pharmaceuticals (United States)
  • Ironwood Pharmaceuticals, Inc. (United States)
  • Astellas Pharma Inc. (Japan)
  • Valeant Pharmaceuticals (Canada)
  • Ardelyx, Inc. (United States)
  • Sebela Pharmaceuticals (Ireland)
Additional players considered in the study are as follows:
Probi (Sweden) , Alfasigma USA, Inc. (Italy) , RedHill Biopharma Ltd. (Israel) , AstraZeneca (United Kingdom) , Ipsen (France) , Takeda Pharmaceutical Company Ltd (Japan) , Synthetic Biologics, Inc. (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 227 Pages 86 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global (United States, European Union and China) IBS Treatment Quantitative research analysis
Global (United States, European Union and China) IBS Treatment Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Novartis AG (Switzerland), Abbott Laboratories (United States), Synergy Pharmaceuticals, Inc. (United States), Allergan Plc (Ireland), Sucampo Pharmaceuticals (United States), Ironwood Pharmaceuticals, Inc. (United States), Astellas Pharma Inc. (Japan), Valeant Pharmaceuticals (Canada), Ardelyx, Inc. (United States) and Sebela Pharmaceuticals (Ireland) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Growing adoption of inorganic strategies by manufacturer" is seen as one of major influencing trends for IBS Treatment Market during projected period 2023-2030.
The IBS Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global (United States, European Union and China) IBS Treatment Report?

Have a Query? Click Here

Other Related Reports

Antibody Drug Conjugates Comprehensive Study by Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumor), Technology (Cleavable Linker, Non-Cleavable Linker), Drugs Type (A...
$ 3450
Swine Diseases Treatment Comprehensive Study by Type (Drugs, Vaccines), Application (Private Veterinary Hospitals, Private Veterinary Pharmacies, Government Veterinary Clinics, Others), Drugs (Anti-I...
$ 3750
Patient Lateral Transfer Comprehensive Study by Type (Air-assisted Lateral Transfer Mattress (Regular Mattress, Split-leg Mattress, Half Mattress), Air-assisted Lateral Transfer Mattress (Reusable Ai...
$ 3750
Clinical Workflow Solution Comprehensive Study by Type (Data Integration, EMR Integration, Nurse Call Systems, Unified Communications, Care Solutions, Patient Flow Management Enterprise Solutions), A...
$ 3650
Renal Function Test Comprehensive Study by Type (Disposables, Reagents, Dipsticks, Other Products), Application (Hospitals, Clinics, Diagnostic Laboratories, Others), Parameters (Serum Urea (15-45 mg...
$ 3750
Chronic Diseases Management Comprehensive Study by Application (Ambulatory Care Centers, Hospitals and Physician Groups, Diagnostic Centers, Home Healthcare Agencies and Nursing Homes, Others), Disea...
$ 3450